Sanofi, the French multinational pharmaceutical giant, has announced the acquisition of Dren Bio’s immunology unit for $600 million upfront, with up to $1.3 billion in additional milestone payments.
This strategic acquisition focuses on expanding Sanofi’s presence in autoimmune disease treatments, particularly with the inclusion of DR-0201, a promising drug in development.
The deal, expected to close in Q2 2025, solidifies Sanofi’s commitment to strengthening its immunology portfolio and advancing its role in the growing autoimmune disease market.